A buffered form of creatine does not promote greater changes in muscle creatine content, body composition, or training adaptations than creatine monohydrate

Table 13 Whole blood markers

Marker	N	Group	Day				p-level
			0	7	28
WBC (x10³/ul)	9	KA-L	5.73 ± 0.6	6.13 ± 0.5	6.17 ± 1.5	Group	0.95
	12	KA-H	5.83 ± 1.1	5.76 ± 0.9	6.36 ± 1.1	Time	0.16
	12	CrM	5.97 ± 1.2	5.73 ± 1.0	5.98 ± 1.2	G x T	0.45
RBC (x10⁶/ul)	9	KA-L	5.44 ± 0.4	5.38 ± 0.5	5.44 ± 0.3	Group	0.28
	12	KA-H	5.10 ± 0.4	5.18 ± 0.3	5.23 ± 0.3	Time	0.91
	12	CrM	5.42 ± 0.5	5.41 ± 0.5	5.35 ± 0.7	G x T	0.64
Hematocrit (%)	9	KA-L	48.4 ± 3.4	47.9 ± 4.3	48.1 ± 2.9	Group	0.17
	12	KA-H	46.5 ± 3.2	47.0 ± 2.8	47.4 ± 1.8	Time	0.96
	12	CrM	45.9 ± 2.3	46.1 ± 2.5	45.2 ± 5.4	G x T	0.65
Hemoglobin (g/dl)	9	KA-L	16.0 ± 1.6	16.0 ± 1.6	16.0 ± 1.2	Group	0.21
	12	KA-H	15.2 ± 1.2	15.7 ± 1.0	15.6 ± 0.7	Time	0.60
	12	CrM	15.1 ± 0.9	15.2 ± 1.1	14.9 ± 2.0	G x T	0.62
MCV (fL)	9	KA-L	89.0 ± 2.8	88.9 ± 2.9	88.3 ± 2.8	Group	0.10
	12	KA-H	91.1 ± 3.5	90.8 ± 3.1	90.7 ± 3.6	Time	0.03
	12	CrM	85.4 ± 9.2	85.7 ± 9.5	85.0 ± 9.1	G x T	0.56
MCH (pg/cell)	9	KA-L	29.4 ± 1.5	29.6 ± 1.2	29.3 ± 1.2	Group	0.34
	12	KA-H	29.8 ± 1.6	30.2 ± 1.5	28.4 ± 4.9	Time	0.20
	12	CrM	28.1 ± 3.5	28.3 ± 3.7	27.9 ± 3.3	G x T	0.44
MCHC (g/dl)	9	KA-L	33.0 ± 1.3	33.3 ± 0.9	33.2 ± 0.9	Group	0.73
	12	KA-H	32.8 ± 0.9	33.3 ± 0.8	32.9 ± 0.6	Time	0.22
	12	CrM	32.9 ± 1.1	32.9 ± 1.3	32.9 ± 0.8	G x T	0.68
RBCDW (%)	9	KA-L	13.0 ± 0.5	13.0 ± 0.9	12.9 ± 0.7	Group	0.34
	12	KA-H	13.8 ± 1.1	13.7 ± 1.0	13.5 ± 1.5	Time	0.41
	12	CrM	13.7 ± 1.4	13.7 ± 1.7	13.6 ± 1.6	G x T	0.92
Platelet Count (x10³/ul)	9	KA-L	266 ± 45	266 ± 52	280 ± 45	Group	0.12
	12	KA-H	253 ± 54	248 ± 62	269 ± 65	Time	0.32
	12	CrM	222 ± 69	222 ± 74	216 ± 65	G x T	0.48

Values are means ± standard deviations. White and red cell whole blood markers were analyzed by MANOVA with repeated measures. Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels.

ISSN: 1550-2783